Embedded Files
DelveInsight’s “Melanocortin receptors (MCR) Therapies– Target Population, Competitive Landscape, and Market Forecast – 2034” report delivers an in-depth understanding of the MCR, historical and forecasted epidemiology as well as the MCR Therapies market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
Unlock detailed insights into the Melanocortin receptors (MCR) Therapies Market by downloading the comprehensive report from DelveInsight @ Melanocortin receptors (MCR) Therapies Therapeutics Market
Key Takeaways from the Melanocortin receptors (MCR) Therapies Market Report
As per the analysis, the risk of conditions like obesity and HSDD increases with age and lifestyle factors, with Melanocortin receptors (MCR) Therapies offering targeted modulation.
According to DelveInsight, approximately 10% of women in the U.S. are affected by Hypoactive Sexual Desire Disorder, with prevalence varying by age.
According to the American Academy of Ophthalmology, Dry Eye Disease prevalence shows age-related disparity, affecting 8.4% under 60 and up to 20% over 80.
According to the Endocrine Society, Cushing's syndrome and Congenital Adrenal Hyperplasia represent significant unmet needs for Melanocortin receptors (MCR) Therapies.
The leading Melanocortin receptors (MCR) Therapies Companies such as Rhythm Pharmaceuticals, Cosette Pharmaceuticals, Clinuvel Pharmaceuticals, Palatin Technologies, Crinetics Pharmaceuticals, Perspective Therapeutics, and others.
Promising Melanocortin receptors (MCR) Therapies Drugs such as IMCIVREE (Setmelanotide), VYLEESI (Bremelanotide), SCENESSE (Afamelanotide), PL9643, Bivamelagon (LB54640), Atumelnant (CRN04894), and others.
Gain a competitive edge in the Melanocortin receptors (MCR) Therapies Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Melanocortin receptors (MCR) Therapies Treatment Drugs
Melanocortin receptors (MCR) Therapies Epidemiology Segmentation in the 7MM
Total Cases of Selected Indications for MCR therapies
Total Eligible Patient Pool of Selected Indications for MCR therapies
Total Treated Cases of Selected Indications for MCR therapies
Melanocortin receptors (MCR) Therapies Treatment Market The primary treatment for MCR-related conditions includes lifestyle modifications, approved agonists, and targeted therapies. Recent advancements include the approval of IMCIVREE (setmelanotide) by Rhythm Pharmaceuticals in 2020, VYLEESI (bremelanotide) by Cosette Pharmaceuticals in 2019, and SCENESSE (afamelanotide) by Clinuvel Pharmaceuticals in 2019, which enhance treatment options for obesity, HSDD, and EPP. Focusing on the chronic and severe nature of these conditions, the treatment approach is comprehensive; modulation of MCR pathways and control of symptoms is the key treatment target.
Melanocortin receptors (MCR) Therapies Market Insights Melanocortin receptors are a serious, life-threatening condition with no cure, serving as a risk factor for numerous disorders. While there is no established cure, genetic testing is available to identify deficiencies, and treatment involves agonists and modulators, alongside lifestyle changes. IMCIVREE, the most innovative targeted treatment, activates MC4R to regulate appetite and energy.
Discover key developments and opportunities in the Melanocortin receptors (MCR) Therapies Market. Click here to learn more from DelveInsight's latest report @ Melanocortin receptors (MCR) Therapies Market Size
Melanocortin receptors (MCR) Therapies Marketed Drugs
IMCIVREE (Setmelanotide): Rhythm Pharmaceuticals In November 2020, the US Food and Drug Administration approved IMCIVREE (setmelanotide) for chronic weight management in adult and pediatric patients aged 6 years and older with obesity due to POMC, PCSK1, or LEPR deficiency. IMCIVREE is a melanocortin-4 (MC4) receptor agonist that activates MC4R to regulate hunger and energy expenditure.
VYLEESI (Bremelanotide): Cosette Pharmaceuticals In June 2019, the US FDA approved VYLEESI (bremelanotide) for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). VYLEESI is a melanocortin receptor agonist that activates MC4R to modulate sexual desire.
Melanocortin receptors (MCR) Therapies Emerging Drugs
PL9643 - Palatin Technologies PL9643 is a synthetic, topically applied melanocortin receptor agonist targeting MC1R and MC5R for dry eye disease. In October 2023, Palatin reported positive results from the Phase III MELODY-1 trial, meeting primary and secondary endpoints.
Bivamelagon (LB54640) - Rhythm Pharmaceuticals Bivamelagon is an oral MC4R-specific agonist for acquired hypothalamic obesity. It is currently in Phase II trials, offering a convenient alternative to subcutaneous therapies.
Other novel emerging drugs in the Melanocortin receptors (MCR) Therapies treatment market in different clinical trial phases include - Atumelnant (CRN04894): Crinetics Pharmaceuticals, and others.
Melanocortin receptors (MCR) Therapies Market Outlook The Melanocortin receptors (MCR) Therapies Market is a competitive landscape with targeted therapies entering the market. The metabolic and rare disease drugs market is moderately fragmented, with significant players launching novel agonists. The market competitors are developing not only novel therapies but also diagnostic tools for genetic deficiencies. The expansion of the healthcare sector and favorable regulatory support are fueling the growth of the melanocortin receptor therapies market.
Download DelveInsight's Melanocortin receptors (MCR) Therapies Market report today and stay ahead in this rapidly evolving field. @ Melanocortin receptors (MCR) Therapies Clinical Trials
Scope of the Melanocortin receptors (MCR) Therapies Market Report
Coverage- Global
Study Period- 2020-2034
Melanocortin receptors (MCR) Therapies Companies- Rhythm Pharmaceuticals, Cosette Pharmaceuticals, Clinuvel Pharmaceuticals, Palatin Technologies, Crinetics Pharmaceuticals, Perspective Therapeutics, and others.
Melanocortin receptors (MCR) Therapies Drugs- IMCIVREE (Setmelanotide), VYLEESI (Bremelanotide), SCENESSE (Afamelanotide), PL9643, Bivamelagon (LB54640), Atumelnant (CRN04894), and others.
Melanocortin receptors (MCR) Therapies Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Melanocortin receptors (MCR) Therapies Unmet Needs, KOL's views, Analyst's views, Melanocortin receptors (MCR) Therapies Market Access and Reimbursement
Download the report to understand which factors are driving Melanocortin receptors (MCR) Therapies Market Trends @ Melanocortin receptors (MCR) Therapies Market Trends
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary of MCR Therapies
4 Key Events
5 Epidemiology and Market Forecast Methodology
6 MCR Therapies Market Overview at a Glance in the 7MM
7 MCR Therapies: Background and Overview
8 Target Patient Pool
9 Marketed Competitors
10 Emerging Therapies
11 MCR Therapies: Seven Major Market Analysis
12 Market Access and Reimbursement
13 SWOT Analysis
14 KOL Views
15 Unmet Needs
16 Appendix
17. DelveInsight Capabilities
18. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
Page updated
Google Sites
Report abuse